Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIMIOTCMKTS:BIOAFOTCMKTS:BTCAOTCMKTS:SCRCQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIMIBIMI$0.03+9,900.0%$0.00$0.00▼$2.01$348K-0.562,853 shs564 shsBIOAFBioasis Technologies$0.00$0.00$0.00▼$0.01$16K0.522,910 shsN/ABTCABactolac Pharmaceutical$120,000.00$120,000.00$120,000.00▼$120,000.00N/A0.01N/AN/ASCRCQScripsAmerica$0.00$0.00▼$0.00$14K-0.46617,500 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIMIBIMI+9,900.00%+9,900.00%+9,900.00%+14,900.00%-98.57%BIOAFBioasis Technologies0.00%0.00%+100.00%-50.00%-95.00%BTCABactolac Pharmaceutical0.00%0.00%0.00%0.00%0.00%SCRCQScripsAmerica0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIMIBIMIN/AN/AN/AN/AN/AN/AN/AN/ABIOAFBioasis TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABTCABactolac PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ASCRCQScripsAmericaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIMIBIMI 0.00N/AN/AN/ABIOAFBioasis Technologies 0.00N/AN/AN/ABTCABactolac Pharmaceutical 0.00N/AN/AN/ASCRCQScripsAmerica 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIMIBIMI$12.63M0.03N/AN/AN/A∞BIOAFBioasis Technologies$30K0.53N/AN/AN/A∞BTCABactolac PharmaceuticalN/AN/AN/AN/AN/AN/ASCRCQScripsAmericaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIMIBIMI-$22.39MN/A0.00∞N/AN/AN/AN/AN/ABIOAFBioasis Technologies-$2.36MN/A0.00∞N/AN/AN/AN/AN/ABTCABactolac PharmaceuticalN/AN/A0.00∞N/AN/AN/AN/AN/ASCRCQScripsAmericaN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIMIBIMIN/AN/AN/AN/AN/ABIOAFBioasis TechnologiesN/AN/AN/AN/AN/ABTCABactolac PharmaceuticalN/AN/AN/AN/AN/ASCRCQScripsAmericaN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIMIBIMI0.11%BIOAFBioasis TechnologiesN/ABTCABactolac PharmaceuticalN/ASCRCQScripsAmericaN/AInsider OwnershipCompanyInsider OwnershipBIMIBIMI69.02%BIOAFBioasis TechnologiesN/ABTCABactolac Pharmaceutical41.40%SCRCQScripsAmericaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIMIBIMI52011.59 million3.59 millionNot OptionableBIOAFBioasis TechnologiesN/A79.41 millionN/ANot OptionableBTCABactolac Pharmaceutical126N/AN/ANot OptionableSCRCQScripsAmerica21140.74 millionN/ANot OptionableBIOAF, SCRCQ, BIMI, and BTCA HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comMedia Sentiment Over TimeBIOAF, SCRCQ, BIMI, and BTCA Company DescriptionsBIMI NASDAQ:BIMI$0.03 +0.03 (+9,900.00%) As of 06/16/2025 11:44 AM EasternBIMI Holdings Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes varieties of products, including raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services; and operates two private hospitals in China. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BIMI International Medical Inc. and changed its name to BIMI Holdings Inc. in January 2024. BIMI Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.Bioasis Technologies OTCMKTS:BIOAF$0.0002 0.00 (0.00%) As of 06/13/2025Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.Bactolac Pharmaceutical OTCMKTS:BTCA$120,000.00 0.00 (0.00%) As of 09/18/2017Bactolac Pharmaceutical, Inc. engages in the research, development and commercialization of vitamins and neutraceuticals. It offers nutritional supplements and shake powders, resveratrol, probiotics, multivitamins, antioxidant products, sports and hormone supplements, and weight loss and detoxification drugs. The company was founded by Pailla Malla Reddy in 1995 and is headquartered in Hauppauge, NY.ScripsAmerica OTCMKTS:SCRCQScripsAmerica, Inc. develops and sells non-sterile topical and transdermal pain creams. The company also provides pharmacy dispensing services for individual doctors, as well as billing and administrative services to independent pharmacies. In addition, it distributes pharmaceutical products to independent pharmacies and other medical providers. The company was founded in 2008 and is based in Clifton, New Jersey. On February 8, 2017, the voluntary petition of ScripsAmerica, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 7, 2016. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
